-
BMO Capital Reiterates Bullish Take on ZIOPHARM (ZIOP) Following Meetings; Co. Considering Strategic Options as CAR-T Progresses
-
Ziopharm Oncology (ZIOP) Prices 10M COmmon Offering at $8.75/Share
-
Ziopharm Oncology (ZIOP) to Commence $75M Stock Offering
-
ZIOPHARM Oncology Announces Proposed Public Offering of Common Stock
-
ZIOPHARM (ZIOP) Bullish Stance Reiterated at BMO Capital Following Meeting with Dr. at MD Anderson
-
ZIOPHARM (ZIOP) Bullish Stance Reiterated at BMO Capital Following MSKCC Pre-Clinical CAR-T Data
-
BMO Capital Came Away from ZIOPHARM (ZIOP) Meeting 'Impressed'
-
BMO Capital Upgrades ZIOPHARM Oncology (ZIOP) Two-Notches to Outperform; 'CAR-T Alliance Is Transformational'
-
BMO Capital Downgrades ZIOPHARM Oncology (ZIOP) to Underperform
-
BMO Starts Biotech Stocks: AMGN, HGSI, REGN, CELG at Outperform, AMLN, GILD, ARNA at Market Perform, BIIB at Underperform
-
Notable Analyst Rating Changes 02/09: UBS, BIDU, NYX, AN Upgraded; KEY, CMS, ILMN, JOE Downgraded
-
Morning Movers 5/27: JSDA, FSII, ACFC, MOV, NTAP, RODM, PAY Higher; ZIOP Lower

